SanegeneBio raises over $110M Series B after Lilly RNAi deal
SanegeneBio has raised over $110 million in a Series B financing completed on December 8, 2025.135
The round includes a strategic investment from Eli Lilly, following SanegeneBio’s earlier RNAi licensing and research collaboration with Lilly announced on November 8, 2025.34
Additional investors in the Series B include an unnamed industrial investor, an unnamed sovereign wealth fund, Sino Biopharm, Legend Capital, Vivo Capital, Invus, SymBiosis, Guofa Capital, TruMed, Lake Bleu Capital, Qiming Venture Partners, K2 Venture Partners, TF Capital, Oriza Holdings, and Northern Light Venture Capital, among others.156
SanegeneBio is an RNAi-focused biotech developing therapeutics that target both liver and extrahepatic tissues, with a trio of Phase 2 liver assets as its most advanced clinical programs.15
The company states that the Series B proceeds will be used to advance its clinical-stage RNAi assets toward registrational studies and accelerate development of additional programs, including those in metabolic and complement-mediated diseases.15
The financing closely follows SanegeneBio’s RNAi licensing and research collaboration with Lilly, which centers on metabolic disease targets (inferred from the Lilly deal context) and positions Lilly as both a strategic partner and investor.34
Recent 2025 pipeline milestones around the time of the raise include:
Phase 1 clinical data for SGB-9768 (a C3 RNAi candidate with FDA orphan drug designation) presented at ASN Kidney Week 2025, and Phase 1 data for SGB-3908 presented at the AHA 2025 meeting, underscoring the maturing clinical portfolio the Series B will fund.4
Coverage of the transaction in fundraising trackers describes SanegeneBio as using the capital to fuel its clinical candidates toward registrational studies and highlights the breadth of its RNA-based platform pipeline.1
VC firm SymBiosis lists the deal on its news page dated December 9, 2025, confirming participation in the Series B syndicate and the timing of the close.6
Sources:
1. https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-25
3. https://www.lqventures.com/lucid-diligence-brief-sanegenebio-rnai-110-million-series-b/
4. https://www.sanegenebio.com/news/
5. https://www.sanegenebio.com/sanegenebio-raises-over-110-million-in-series-b-financing/